GENB
Generate Biomedicines, Inc.
$12.90
+2.71% 2026-10-20
Healthcare
GENBSPY
1W
+5.2%
1M
-24.7%
3M
-10.4%
6M
+1.8%
YTD
–
1Y
–
Live chart
Loading live chart…
Grades vs sector
MomentumNot enough data yet–
Momentum
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
GrowthNot enough data yet–
Growth
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Value
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ProfitabilityNot enough data yet–
Profitability
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15not ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsZealand Pharma pens $1.2bn AI obesity drug discovery pact with Generate
Pharmaceutical Technology · Oct 14
Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market
Benzinga · Oct 14
Generate Biomedicines, Zealand Pharma Report Partnership
MT Newswires · Oct 13
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
GlobeNewswire · Oct 13
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
GlobeNewswire · Oct 13
Key stats
Market cap$1.7B
P/E (trailing)–
P/E (forward)-5.7
52-week range11.00 – 22.67
Revenue growth (YoY, latest qtr)-37.7%
Dividend yield0.00%
Analyst consensusStrong Buy (5)
Mean price target$27.00 (+109%)
Valuation and fundamentals
Valuation & fundamentals
No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).
Earnings
Next report: 2026-11-05 · before open · EPS est -0.55
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | -0.49 | -0.52 | -5.6% |
| 2026-05-07 | -0.51 | -1.07 | -111.2% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $6.3M | – |
| 2026-03-31 | $7.2M | – |
| 2025-06-30 | $10.1M | – |
| 2025-03-31 | $8.8M | – |
Analyst actions
HC Wainwright & Co.
PT $30
2026-10-05 · reit
Buy → BuyPT $30
HC Wainwright & Co.
PT $30
2026-09-08 · reit
Buy → BuyPT $30
HC Wainwright & Co.
PT $30
2026-08-28 · main
Buy → BuyPT $30
Morgan Stanley
PT $22
2026-05-14 · main
Overweight → OverweightPT $22
HC Wainwright & Co.
PT $25
2026-05-08 · main
Buy → BuyPT $25
HC Wainwright & Co.
PT $16
2026-04-13 · init
→ BuyPT $16
Insider trades
Arnold Frances
$16.0K
Director · 2026-09-01
SELL$16.0K
Stats refreshed 2026-10-20 18:13:49 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.